[1] Bhattacharya S, Mishra RK: Fibrous dysplasia and cherubism [J]. Indian J Plast Surg, 2015, 48∶236-248 [2] Degala S, Mahesh KP, Monalisha: Cherubism: a case report [J]. J Maxillofac Oral Surg, 2015,14∶258-262 [3] Mehrotra D, Kesarwani A, Nandlal: Cherubism: case report with review of literature [J]. J Maxillofac Oral Surg, 2011, 10∶64-70 [4] Li CY, Yu SF: A novel mutation in the SH3BP2 gene causes cherubism: case report [J]. BMC Med Genet, 2006, 7∶84 [5] Sekerci AE, Balta B, Dundar M, et al. A c.1244G>A (p.Arg415Gln) mutation in SH3BP2 gene causes cherubism in a Turkish family: report of a family with review of the literature [J]. Med Oral Patol Oral Cir Bucal, 2014, 19∶e340-344 [6] Mirmohammadsadeghi A, Eshraghi B, Shahsanaei A, et al. Cherubism: report of three cases and literature review [J]. Orbit, 2015, 34∶33-37 [7] GuezGuez A, Prod'homme V, Mouska X, et al. 3BP2 adapter protein is required for receptor activator of NFkappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells [J]. J Biol Chem, 2010, 285∶20952-20963 [8] Carvalho VM, Perdigao PF, Amaral FR, et al. Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism [J]. Oral Dis, 2009, 15∶106-110 [9] Deckert M, Prod'Homme V. SH3BP2 heterozygous mutation amplifies macrophage inflammatory responses to infection in a mouse model of cherubism [J]. Med Sci (Paris), 2015, 31∶589-591 [10] 许舒宇,李翠英,徐欣,等.巨颌症致病基因SH3BP2突变体对成纤维细胞的增殖抑制作用研究[J].口腔医学研究,2014,30(1)∶5-8+12 [11] Reichenberger EJ, et al. The role of SH3BP2 in the pathophysiology of cherubism [J]. Orphanet J Rare Dis, 2012. 7(Suppl 1)∶p. S5 [12] Tager AM, Kradin RL, LaCamera P, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10 [J]. Am J Respir Cell Mol Biol, 2004, 31∶395-404 [13] Keane MP, Belperio JA, Arenberg DA, et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis [J]. J Immunol, 1999, 163∶5686-5692 [14] Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome [J]. J Immunol, 2002, 169∶1037-1049 [15] Jiang D, Liang J, Campanella GS, et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4 [J]. J Clin Invest, 2010, 120∶2049-2057 [16] Prod'Homme V, Boyer L, Dubois N, et al. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages. J Clin Invest, 2015, 125∶1396-1400 [17] Singer AJ, Clark RA. Cutaneous wound healing [J]. N Engl J Med, 1999, 341∶738-746 [18] Peranteau WH, Zhang L, Muvarak N, et al. IL10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation [J]. J Invest Dermatol, 2008, 128:1852-1860 [19] Shi JH, Guan H, Shi S, et al. Protection against TGF-beta1-induced fibrosis effects of IL10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring [J]. Arch Dermatol Res, 2013, 305∶341-352 [20] Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action [J]. Blood, 1999, 94∶984-993 [21] Westerly BD, Johnson GB, Maldonado F, et al. Targeting B lymphocytes in progressive fibrosing mediastinitis [J]. Am J Respir Crit Care Med, 2014, 190∶1069-1071 [22] Francois A, Gombault A, Villeret B, et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis [J]. J Autoimmun, 2015, 56∶1-11 |